TY - JOUR
T1 - Effectiveness and safety of immune checkpoint inhibitors in combination with palliative radiotherapy in advanced melanoma
T2 - A systematic review
AU - Ben Shimol, Jennifer
AU - Guzman-Prado, Yuli
AU - Karlinskaya, Maria
AU - Davidson, Tima
N1 - Publisher Copyright:
© 2021 Elsevier B.V.
PY - 2021/11
Y1 - 2021/11
N2 - Background: Radiotherapy is frequently added to immune checkpoint inhibitors (ICI) when treating melanoma. We sought to describe the efficacy of combination ICI and palliative radiotherapy (pRT) and assess safety, focusing on immune related adverse events (irAE). Methods: A systematic search for studies investigating the combination of pRT and ICI was conducted. Results: Five hundred-two articles were identified; nine met inclusion criteria. Improvements in objective response rate (p = 0.02), complete response (p = 0.04), and one-year local control (p < 0.005) were demonstrated when pRT was added to ICI. While some studies revealed improved overall and progression free survival, findings were mixed. No significant increases in adverse events or irAE were seen with the combined treatment compared with ICI alone. Conclusion: The included studies revealed that the addition of pRT to ICI is effective and safe in patients with advanced melanoma. Measures of survival varied. More studies are warranted to identify optimal conditions for combination treatment.
AB - Background: Radiotherapy is frequently added to immune checkpoint inhibitors (ICI) when treating melanoma. We sought to describe the efficacy of combination ICI and palliative radiotherapy (pRT) and assess safety, focusing on immune related adverse events (irAE). Methods: A systematic search for studies investigating the combination of pRT and ICI was conducted. Results: Five hundred-two articles were identified; nine met inclusion criteria. Improvements in objective response rate (p = 0.02), complete response (p = 0.04), and one-year local control (p < 0.005) were demonstrated when pRT was added to ICI. While some studies revealed improved overall and progression free survival, findings were mixed. No significant increases in adverse events or irAE were seen with the combined treatment compared with ICI alone. Conclusion: The included studies revealed that the addition of pRT to ICI is effective and safe in patients with advanced melanoma. Measures of survival varied. More studies are warranted to identify optimal conditions for combination treatment.
KW - Immune checkpoint inhibitors
KW - Immune-related adverse events
KW - Immunotherapy
KW - Melanoma
KW - Palliative
KW - Radiotherapy
UR - http://www.scopus.com/inward/record.url?scp=85117751333&partnerID=8YFLogxK
U2 - 10.1016/j.critrevonc.2021.103499
DO - 10.1016/j.critrevonc.2021.103499
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???
C2 - 34687896
AN - SCOPUS:85117751333
SN - 1040-8428
VL - 167
JO - Critical Reviews in Oncology/Hematology
JF - Critical Reviews in Oncology/Hematology
M1 - 103499
ER -